The stock of Heron Therapeutics Inc (NASDAQ:HRTX) is a huge mover today! About 686,156 shares traded hands. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 31.11% since April 27, 2016 and is downtrending. It has underperformed by 36.33% the S&P500.
The move comes after 7 months positive chart setup for the $583.72 million company. It was reported on Nov, 30 by Barchart.com. We have $16.73 PT which if reached, will make NASDAQ:HRTX worth $52.53 million more.
Analysts await Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings on February, 17. They expect $-1.07 earnings per share, down 22.99% or $0.20 from last year’s $-0.87 per share. After $-1.24 actual earnings per share reported by Heron Therapeutics Inc for the previous quarter, Wall Street now forecasts -13.71% EPS growth.
Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage
Out of 7 analysts covering Heron Therapeutics (NASDAQ:HRTX), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 11 analyst reports since August 3, 2015 according to StockzIntelligence Inc. As per Monday, August 3, the company rating was maintained by Brean Capital. The rating was initiated by Bank of America with “Buy” on Wednesday, September 2. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) has “Buy” rating given on Wednesday, September 23 by Jefferies. Aegis Capital initiated the stock with “Buy” rating in Wednesday, October 26 report. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Lake Street on Thursday, December 10. On Wednesday, September 23 the stock rating was maintained by Leerink Swann with “Outperform”. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) earned “Buy” rating by Brean Capital on Monday, August 10.
According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”
More news for Heron Therapeutics Inc (NASDAQ:HRTX) were recently published by: Businesswire.com, which released: “Susan G. Komen® Joins Forces With Heron Therapeutics to Raise Awareness of the …” on November 29, 2016. Marketwatch.com‘s article titled: “Heron Therapeutics shares rise 18% in pre-market trade after company said …” and published on August 10, 2016 is yet another important article.
HRTX Company Profile
Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.